In hepatocellular carcinoma (HCC), KIF26B activation was suggested to promote cancer progression by activating the phosphatidylinositol 3-kinase (PI3K) and Akt/Protein Kinase B (PI3K/Akt) signaling pathway (30). Here, AKT1 is linked to cancer.